Niklas Klümper, Resident in Urology and Researcher at the Institute for Experimental Oncology at the University Hospital Bonn, shared on X/Twitter:
“Happy to share our commentary about EV-302 in Journal of European Urology.
– Thanks to Markus Eckstein, Boris Hadaschik and Viktor Grünwald.
Identification of patients with low or minimal chances of benefiting from EV/P is crucial, as there are other effective therapies available (eg, chemoimmunotherapy) or in late-stage clinical development.
Loss of target protein NECTIN4 is an intuitive predictive biomarker. Close correlation between ADC target and response is well-established (eg, Her2-ADC).
We believe that assessment of NECTIN4 status will help in achieving optimal integration of EV/P into standard of care!”
Proceed to the article.
Source: Niklas Klümper/X